Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04815850
Other study ID # 0810
Secondary ID
Status Completed
Phase
First received
Last updated
Start date March 1, 2021
Est. completion date December 5, 2022

Study information

Verified date May 2022
Source University of Leicester
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Patients on haemodialysis are at higher risk of getting a severe form of COVID-19 if they become infected. Vaccinations are soon to arrive and offer great hope of controlling the current pandemic. It is likely that patients on haemodialysis will be amongst the first people to be offered vaccination against COVID-19 when they become available. While any vaccines offered to these patients will be safe to receive, the effectiveness of the vaccines at giving immunity to being infected with COVID-19 are not known as they have not been explicitly tested in patients on haemodialysis. This study will involve having 3 blood tests to test for an antibody response following vaccination for COVID-19. The first will be 1 month after the first vaccination dose to look at the initial antibody response and the second and third will be 1 month and 6 months after the second vaccination dose.


Description:

Patients with end stage kidney disease (ESKD) on haemodialysis are more likely to suffer poorer outcomes following infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. This is likely to be because these patients have higher levels of co-morbid diseases and they are relatively immunosuppressed due to the effects of advanced kidney disease. The humoral response against common viral vaccination is known to be blunted in patients with ESKD and there are data to suggest seroconversion following infection with COVID-19 is blunted in patients with kidney disease. A successful programme of vaccination will undoubtedly improve outcomes for patients on haemodialysis, but vaccine testing programmes have not included patients with ESKD. Whilst initial press-coverage of the efficacy of vaccines which are available for use is promising, they are untested in patients on haemodialysis who are known to be relatively immunosuppressed as a result of their renal disease and as such the efficacy for this patient group is not known. This study will phenotype the IgG antibody response to vaccination for COVID-19 in 100 patients on haemodialysis compared to 50 healthy volunteers. Antibody testing will be conducted at 1 month post first vaccination dose and 1 month and 6 months post second vaccination dose. This will give crucial information as to the efficacy of the vaccine and inform possible requirements for re-vaccination. This study will: 1. Phenotype the 1 month IgG antibody response to the first vaccination dose and the 1 month and 6 month response to the second vaccination dose for COVID-19 in patients on haemodialysis 2. Compare the 1 month IgG antibody response to the first vaccination dose and the 1 month and 6 month response to the second vaccination dose for COVID-19 between patients on haemodialysis and healthy volunteers


Recruitment information / eligibility

Status Completed
Enrollment 115
Est. completion date December 5, 2022
Est. primary completion date February 15, 2022
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - End stage kidney disease on haemodialysis - Able and willing to give informed consent - Have completed or due to complete vaccination against COVID-19 Exclusion Criteria: - Acute kidney injury requiring temporary haemodialysis - Unable to give informed consent - Pregnancy

Study Design


Locations

Country Name City State
United Kingdom University Hospital Leicester NHS Trust Leicester Leicestershire

Sponsors (3)

Lead Sponsor Collaborator
University of Leicester Francis Crick Institute, Leicester Hospitals Charity

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in COVID-19 IgG antibody (RLU) Measured from a serum blood sample Baseline; 1 month post first vaccine; 1 month post second vaccine; 6 months post second vaccine
See also
  Status Clinical Trial Phase
Recruiting NCT04319185 - Assisted Peritoneal Dialysis: A Feasibility Study N/A
Recruiting NCT06056739 - Alio WEAR Study: Long-term Wear of the Alio Platform N/A
Recruiting NCT05311956 - Pain Reduction Using NEurostimulation Study N/A
Active, not recruiting NCT05485961 - Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis Phase 2/Phase 3
Completed NCT02939586 - The Effect of Haemodialysis in Sleep Apnoea N/A
Completed NCT00792454 - Reduction of Mortality Prior to and During the First 90 Days of Dialysis Through a Renal Rehabilitation Program N/A
Recruiting NCT03586518 - Validating Novel, Non-contrast Cardiac MRI Imaging in Haemodialysis Patients
Completed NCT02513303 - Trial to Evaluate the Sirolimus-Eluting Collagen Implant on AV Fistula Outcomes Phase 3
Recruiting NCT05642156 - Hemodynamics in Chronic Hemodialysis Patients Undergoing Isolated Ultrafiltration Compared to Conventional Hemodialysis N/A
Not yet recruiting NCT05774392 - An Observational Study of Patients With Chronic Kidney Disease
Completed NCT01877863 - The Effect of Intradialytic Exercise on the Functional Capacity of Hemodialysis Patients N/A
Completed NCT01859871 - Evaluation of a Website on Living Kidney Donation for Hispanics N/A
Completed NCT00649298 - A Clinical Trial of IntensiVE Dialysis Phase 4
Recruiting NCT05836220 - Parathyroid Hormone (PTH) Attenuation Trial in Hemodialysis-2 Phase 3
Completed NCT04912024 - Comparative Outcome Measures of Patients Receiving Acute Renal ThErapy Study
Not yet recruiting NCT06356168 - Virtual Reality in End Stage Kidney Disease N/A
Not yet recruiting NCT05558267 - Potassium Containing Salt-Substitute in Hemodialysis-Dependent End Stage Kidney Disease N/A
Completed NCT01530945 - Mapping Multidimensional Illness Trajectories of Patients With End-stage Kidney Disease N/A
Recruiting NCT05738330 - Symptom Monitoring in Hemodialysis N/A
Completed NCT02475551 - Study to Evaluate the Safety, Tolerability, Efficacy and PK of IdeS in Kidney Transplantation Phase 2